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Thrombosis on the substrate of  a disrupted 
atheromatous plaque causes most acute coronary 
events. The physical integrity of the plaque, notably 
of  the extracellular matrix of  the fibrous capsule 
overlying the atheroma's thrombogenic lipid core, 
thus governs the most important clinical manifesta- 
tions of  atherosclerosis. Stable atheroma generally 
has thick fibrous caps and lipid pools smaller than 
lesions that have ruptured. Accumulating evidence 
supports akey role for inflammation as another crit- 
ical determinant of  the stability of  human athero- 
sclerotic plaques. Plaques that rupture generally 
have more abundant leukocytic infiltrates than 
those considered stable. Inflammatory mediators 
such as cytokines can influence several biological 
processes that regulate stability of  the plaque's 
fibrous cap, hence its resistance to rupture. For 
example, gamma interferon, produced by activated 
T lymphocytes within atheroma inhibits the pro- 
duction of interstitial forms of collagen by human 
vascular smooth muscle cells. Inf lammatory 
cytoldnes uch as interleukin-1, tumor necrosis fac- 
tor (TNF), and the cell surface homolog of TNF-a 
known as CD-40 ligand can also elicit the expres- 
sion by macrophages and smooth muscle cells of  
enzymes that can weaken the xtracellular matrix. 
Foam cells derived from both macrophages and 
smooth muscles also express active matrix-degrad- 
ing enzymes. We have hypothesized that lipid low- 
ering reduces timuli for the inflammatory response 
within the complicated atherosclerotic lesion. 
Classical studies in nonhuman primates uggested 
that lipid lowering produces qualitative changes in 
plaques more complex than mere "regression." 
Recent data from experimental studies in rabbits 
indicate that lipid lowering can reduce inflamma- 
tion in the atheroma, monitoring modern markers 
of vascular cell functions related to atheroma stabil- 
ity. In particular, lipid lowering by diet can reduce 
the number of  macrophages in plaques, and their 
expression of  such mediators of  plaque instability 
such as collagen-degrading matrix metallopro- 
teinases. Moreover, the collagen content of plaques 
increases during chronic lipid lowering, rendering 
plaques less friable and more resistant o rupture. 
After lipid-lowering smooth muscle cells in the 
plaque exhibit a more mature phenotype, using the 
expression of myosin isoforms as a molecular mark- 
cr. Macrophages and smooth muscle cells within 
plaques have reduced expression of  the potent pro- 
coagulant, tissue factor, a major instigator of  
thrombosis on disrupted atherosclerotic plaques. 
Such observations provide a mechanistic basis for 
understanding the marked reduction in acute coro- 
nary events observed in patients treated with agents 
that reduce their serum cholesterol levels. 
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Imaging techniques currently used to identify 
preclirdcal atherosclerotic lesions include measure- 
ment of carotid intima-media thickness (IMT) with 
B-mode ultrasound, coronary calcium scoring using 
electron beam computerized tomography (EBCT) 
or ultra-fast helical CT, endothelial function studies 
using B-mode ultrasound, and magnetic resonance 
imaging (MRI) of  the arterial wall. 1-6 With the 
exception of EBCT, each of  these technologies i
widely available in the clinical as well as the research 
setting. 
It is accepted that individuals with established 
coronary heart disease (CHD) benefit from aggres- 
sive medical intervention. Such intervention, termed 
secondary prevention, is directed at reducing mor- 
bidity and mortality in individuals at risk for recur- 
rent events. In contrast, primary prevention focuses 
